Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy

Hideyuki Okuma, Ryotaro Bouchi, Seizaburo Masuda, Takato Takeuchi, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 52-year-old woman was treated with sensor augmented pump therapy after undergoing total pancreatectomy for a nonfunctional pancreatic neuroendocrine tumor (NET). The secretion of both endogenous insulin and pancreatic glucagon were completely depleted. Octreotide long acting repeatable (Oct-LAR) was administered for the treatment of liver metastasis of NET. Both the fasting and postprandial glucagon levels decreased immediately after the administration of Oct-LAR. In a continuous glucose monitoring analysis, episodes of nocturnal hypoglycemia was found to increase and an improvement of postprandial hyperglycemia was observed. This case suggests that octreotide may reduce the glucose level in both the fasting and postprandial states, in part by the suppression of extrapancreatic glucagon.

Original languageEnglish
Pages (from-to)3061-3066
Number of pages6
JournalInternal Medicine
Volume56
Issue number22
DOIs
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy'. Together they form a unique fingerprint.

  • Cite this